biotech / news / / MarketScreener
AstraZeneca generated $15.29 billion in revenue compared with $13.59 billion in the year-earlier period.
AstraZeneca's first-quarter revenue surpassed analyst expectations, reaching $15.29 billion versus $14.94 billion forecasted.
KEY POINTS
- Oncology now represents about 44% of AstraZeneca’s total revenue and leads its late-stage pipeline.
- Sales of oncology and rare-disease drugs achieved double-digit growth during this quarter.
- AstraZeneca maintained its full-year guidance, expecting mid to high single-digit revenue growth.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →